And this is what sparked Lowes attention as Sandozs chief executive officer (CEO), Richard Saynor, told Endpoint News that the company was planning to launch a GLP-1 generic in Canada as soon as governmental protection of semaglutide expires in 2026, because, according to him, Novo didnt have the patent to protect it further
and Medco Health Solutions, Inc
The full implications of this change are still unfolding, with legal challenges and regulatory clarifications ongoing
Certified Quality & Safety Manufactured in a WHO-GMP, HACCP, ISO & FSSAI certified facility
I look at the full metabolic picture: weight history, body composition, appetite patterns, lab results, medications, lifestyle, and long-term goals